ARDX Key Statistics, Chart & Performance
The current stock price of ARDX is 5.74 USD. In the past month the price decreased by -3.2%. In the past year, price increased by 10.17%.
ARDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ARDX
Company Profile
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 395 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Company Info
ARDELYX INC
400 Fifth Avenue, Suite 210
Waltham MASSACHUSETTS 94555 US
CEO: Michael Raab
Employees: 395
Phone: 15107451700
ARDELYX INC / ARDX FAQ
What does ARDELYX INC do?
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 395 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
What is the current price of ARDX stock?
The current stock price of ARDX is 5.74 USD. The price decreased by -4.17% in the last trading session.
Does ARDELYX INC pay dividends?
ARDX does not pay a dividend.
How is the ChartMill rating for ARDELYX INC?
ARDX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ARDELYX INC (ARDX) stock?
17 analysts have analysed ARDX and the average price target is 11.83 USD. This implies a price increase of 106.13% is expected in the next year compared to the current price of 5.74.
What sector and industry does ARDELYX INC belong to?
ARDELYX INC (ARDX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for ARDX stock?
ARDELYX INC (ARDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
ARDX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ARDX. When comparing the yearly performance of all stocks, ARDX turns out to be only a medium performer in the overall market: it outperformed 62.07% of all stocks.
ARDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARDX. Both the profitability and financial health of ARDX have multiple concerns.
ARDX Financial Highlights
Over the last trailing twelve months ARDX reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 24.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| Debt/Equity | 1.31 |
ARDX Forecast & Estimates
17 analysts have analysed ARDX and the average price target is 11.83 USD. This implies a price increase of 106.13% is expected in the next year compared to the current price of 5.74.
For the next year, analysts expect an EPS growth of -47.68% and a revenue growth 22.14% for ARDX